Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
Protara Therapeutics, Inc. TARA | 0.00 |
$100,000,000
Common Stock
We have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $100,000,000 through TD Cowen, acting as our agent or principal.
Our common stock is listed on The Nasdaq Global Market, or Nasdaq, under the symbol "TARA." On May 11, 2026, the last reported sale price of our common stock was $5.27 per share.
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be in negotiated transactions, including block trades or block sales, or by any method permitted by law to be deemed an "at the market offering" as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including without limitation sales made through Nasdaq or on any other trading market for our common stock, or by any other method permitted by law. TD Cowen is not required to sell any specific amount of our common stock, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between TD Cowen and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to TD Cowen for sales of common stock sold pursuant to the Sales Agreement will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold thereunder. See "Plan of Distribution" beginning on page S-12 of this prospectus supplement for additional information regarding the compensation to be paid to TD Cowen. In connection with the sale of the common stock on our behalf, TD Cowen may be deemed to be an "underwriter" within the meaning of the Securities Act, and the compensation of TD Cowen may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
